Drug
Jnj 86974680
Jnj 86974680: highest development phase Phase 1, developed by Johnson & Johnson. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Johnson & Johnson
Trials
| Drug | Phase | Indication |
|---|---|---|
| JNJ-86974680 NCT06116786 | Phase 1 | Carcinoma, Non-small-Cell Lung |
Latest
No recent events.
Follow Jnj 86974680 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.